Option chain shows key data for VYNE Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for VYNE Therapeutics.

VYNE Therapeutics (NASDAQ:VYNE) Stock, Option Chain

VYNE THERAPEUTICS INC

VYNE Therapeutics

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

Biotech

News

Health Care

Movers

Trading Ideas

General

VYNE

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on track for mid-2025 results.

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Movers_Stocks

ASAN

CRVO

CUTR

FWRG

GMHS

KUKE

LFMD

LZMH

NPWR

SNOA

SPRC

STSS

TNON

TSVT

Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Long Ideas

Penny Stocks

Pre-Market Outlook

Markets

ALVR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

IBIO

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1

VYNE Therapeutics Inc

Press Releases

VYNE Therapeutics to Participate in September Investor Conferences

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Earnings

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Analyst Ratings

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics to Participate in March Investor Conferences

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Provides Update on VYN202 Program

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NRX Pharmaceuticals

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Talphera

TherapeuticsMD

HC Wainwright & Co.

BTIG

Cantor Fitzgerald

Comments

VYNE Therapeutics

VYNE Therapeutics (VYNE) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell